OICR19451

Overview

OICR19451 is an orally active dual NUAK1 / NUAK2 and MARK2 / MARK3 kinase inhibitor, with IC 50 values of 12 nM and 10 nM against NUAK1 and NUAK2 , and 101 nM and 124 nM against MARK2 and MARK3 , respectively. OICR19451 modulates the Hippo signaling pathway, increases the phosphorylation level of YAP , enhances the cytoplasmic localization of YAP / TAZ , and inhibits the expression of oncogenes. OICR19451 inhibits cancer cell growth, reduces metastasis, promotes tumor capsule formation, and improves mouse survival in an orthotopic breast cancer model. OICR19451 can be used for research related to triple-negative breast cancer .

Application

Products | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Disease Areas > Cancer | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > AMPK | Products > Signaling Pathways > MARK | Products > Signaling Pathways > YAP

Product Information

• Catalog No.: HY-182743
• CAS No.: 2803349-61-1
• Molecular Formula: C26H31ClF2N8O2S
• Molecular Weight: 593.09
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source